Stock BZYR BURZYNSKI RESEARCH INSTITUTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Burzynski Research Institute, Inc.

Equities

BZYR

US1231591058

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 17:16:28 26/06/2024 BST 		5-day change 1st Jan Change
0.0443 USD -11.34% Intraday chart for Burzynski Research Institute, Inc. +46.20% +0.68%
05-29 Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 29, 2024 CI
01-16 Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023 CI

Valuation

Fiscal Period: February 2019 2020 2021 2022 2023 2024
Capitalization 1 2.76 1.446 3.812 3.943 4.831 3.022
Enterprise Value (EV) 1 2.76 1.446 3.812 3.94 4.83 3.021
P/E ratio -1.69 x -0.88 x -3.17 x -3 x -5.27 x -2.26 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF 20.2 x 17.5 x -958 x 95.8 x 51.3 x -131 x
FCF Yield 4.95% 5.71% -0.1% 1.04% 1.95% -0.76%
Price to Book -14.8 x -9.48 x -83.3 x 3,333 x -353 x -120 x
Nbr of stocks (in thousands) 131,448 131,448 131,448 131,448 131,448 131,448
Reference price 2 0.0210 0.0110 0.0290 0.0300 0.0368 0.0230
Announcement Date 29/05/19 28/05/20 24/05/21 26/05/22 25/05/23 29/05/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: February 2019 2020 2021 2022 2023 2024
Net sales - - - - - -
EBITDA - - - - - -
EBIT 1 -1.638 -1.635 -1.302 -0.9767 -0.9163 -1.335
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -1.638 -1.634 -1.204 -0.9767 -0.9163 -1.335
Net income 1 -1.638 -1.634 -1.204 -0.9767 -0.9163 -1.335
Net margin - - - - - -
EPS 2 -0.0125 -0.0124 -0.009159 -0.009999 -0.006970 -0.0102
Free Cash Flow 1 0.1366 0.0825 -0.003978 0.0411 0.0941 -0.023
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 29/05/19 28/05/20 24/05/21 26/05/22 25/05/23 29/05/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: February 2019 2020 2021 2022 2023 2024
Net Debt 1 - - - - - -
Net Cash position 1 0 0 0 0 0 0
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 0.14 0.08 -0 0.04 0.09 -0.02
ROE (net income / shareholders' equity) 1,113% 964% 1,214% 4,376% 14,637% 6,875%
ROA (Net income/ Total Assets) -4,006% -4,863% -7,820% -21,738% -17,370% -39,333%
Assets 1 0.0409 0.0336 0.0154 0.004493 0.005275 0.003395
Book Value Per Share 2 -0 -0 -0 0 -0 -0
Cash Flow per Share 2 0 0 - 0 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 29/05/19 28/05/20 24/05/21 26/05/22 25/05/23 29/05/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BURZYNSKI RESEARCH INSTITUTE, INC. Stock Burzynski Research Institute, Inc.
+0.68% 5.83M
MODERNA, INC. Stock Moderna, Inc.
+16.59% 45.51B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.89% 38.52B
LONZA GROUP AG Stock Lonza Group AG
+38.08% 38.13B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+27.12% 30.74B
CELLTRION, INC. Stock Celltrion, Inc.
-8.64% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.81% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.08% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.85% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.19% 11.29B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BZYR Stock
  4. Financials Burzynski Research Institute, Inc.